ABHD12B

Across TCGA pan-cancer cohorts, ABHD12B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ABHD12B data layer compared with 19 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher ABHD12B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ABHD12B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, KIRP, and LUAD are the cancer types where ABHD12B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.167	0.759	.010	18	view →
KIRP	OS	Median	All	0.216	0.904	<.001	15	view →
LUAD	OS	Median	All	0.274	0.697	.035	3	view →
UCEC	DFS	Median	All	1.000	0.631	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ABHD12B–CESC (OS)

Open the CESC breakdown →